Teva celiac disease candidate granted fast track designation by us fda

Fast track designation granted for investigational tev-53408, an anti-il-15 antibody designation underscores the potential of tev-53408, currently undergoing a phase 2a study for the treatment of celiac disease candidate demonstrates teva's commitment to bringing important new treatment options to underserved patient populations tel aviv, israel, may 27, 2025 (globe newswire) -- teva pharmaceutical industries, ltd. (nyse and tase: teva) today announced that the us food and drug administration (fda) granted fast track designation for investigational tev-53408, an anti-il-15 antibody, for the treatment of people with celiac disease on a gluten-free diet.
TEVA Ratings Summary
TEVA Quant Ranking